Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded to “Buy” at UBS Group

UBS Group upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a neutral rating to a buy rating in a research report released on Monday, MarketBeat Ratings reports.

A number of other research firms have also recently commented on BAYRY. Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 23rd. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday, February 18th. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Trading Up 4.8%

Shares of Bayer Aktiengesellschaft stock opened at $11.52 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The company has a fifty day simple moving average of $12.48 and a 200-day simple moving average of $10.05. The stock has a market cap of $45.27 billion, a price-to-earnings ratio of -10.38 and a beta of 0.69. Bayer Aktiengesellschaft has a 12-month low of $5.30 and a 12-month high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, hitting the consensus estimate of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. The firm had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.